ArticlePloS one2011
Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 77 citations in OpenAlex.
- Global analysis of the Hfq-mediated RNA interactome discovers a MicA homolog that affects the cytotoxicity, biofilm formation, and resistance to complement of Bordetella pertussis.Nucleic acids research · 2025Article
- Outer membrane protein C is a protective and unique vaccine antigen against Shigella flexneri 3a.Scientific reports · 2024Article
- Toward aInternational journal of molecular sciences · 2023Review
- Peptide Sequence of Pili Subunit Protein 49.8 kDaTurkish journal of pharmaceutical sciences · 2022Article
- Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs.Nature microbiology · 2022Article
- Article
- Shigella Outer Membrane Vesicles as Promising Targets for Vaccination.International journal of molecular sciences · 2022Review
- Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies.Frontiers in microbiology · 2022Review
- Recent Progress inPathogens (Basel, Switzerland) · 2021Review
- An OMV-Based Nanovaccine Confers Safety and Protection against PathogenicNanomaterials (Basel, Switzerland) · 2020Article
- Comparison of Humoral Immune Responses to Different Forms ofFrontiers in veterinary science · 2020Article
- Reverse vaccinology approach for the identification and characterization of outer membrane proteins ofClinical and experimental vaccine research · 2020Article
- Oral Deliverable Mucoadhesive Chitosan-International journal of nanomedicine · 2020Article
- Article
- Human Intestinal Enteroids as a Model System ofInfection and immunity · 2019Article
- Article
- Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis.Frontiers in immunology · 2019Article
- Article
- Surface engineered polyanhydride-based oralInternational journal of nanomedicine · 2018Article
- Outer membrane proteins analysis of Shigella sonnei and evaluation of their antigenicity in Shigella infected individuals.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn our earlier studies 34 kDa outer membrane protein (OMP) of Shigella flexneri 2a has been identified as an efficient immunostimulant. KEY
resultsIn the present study MALDI-TOF MS analysis of the purified 34 kDa OMP of Shigella flexneri 2a shows considerable sequence homology (Identity 65%) with the OmpA of S. flexneri 2a. By using the specific primers, the gene of interest has been amplified from S. flexneri 2a (N.Y-962/92) genomic DNA, cloned in pET100/D-TOPO® vector and expressed using induction with isopropyl thiogalactoside (IPTG) for the first time. Immunogenicity and protective efficacy of the recombinant OmpA has been evaluated in an intranasally immunized murine pulmonary model. The recombinant protein induces significantly enhanced protein specific IgG and IgA Abs in both mucosal and systemic compartments and IgA secreting cells in the systemic compartment (spleen). The mice immunized with OmpA have been protected completely from systemic challenge with a lethal dose of virulent S. flexneri 2a. Immunization with the protein causes mild polymorphonuclear neutrophil infiltration in the lung, without inducing the release of large amounts of proinflammatory cytokines.
conclusionThese results suggest that the OmpA of S. flexneri 2a can be an efficacious mucosal immunogen inducing protective immune responses. Our findings also demonstrate that antibodies and Th1 immune response may be associated with the marked protective efficacy of immunized mice after intranasal shigellae infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.